目的：探讨索拉非尼对人肝癌（HCC）细胞体外生长及肿瘤相关基因表达的影响。方法： 用不同浓度（0、5、10、20 μmol/L） 索拉非尼作用人HCC 细胞（Hep3B2.1-7）24 h 后， 用CCK-8 法观察细胞的增殖情况， 并分别用real-time PCR 与Western blot 检测各组HCC 细胞p53、PTEN、TGF-β1 的mRNA 与蛋白表达。结果：与0 μmol/L 索拉非尼处理组（对照组）比较，其余各浓度索拉非尼处理组HCC 细胞增殖均明显降低（均P<0.05）；p53、PTEN 的mRNA 与蛋白表达明显升高，而TGF-β1 的mRNA 与蛋白表达明显降低（均P<0.05），以上作用均呈一定的浓度依赖性。结论：索拉非尼对HCC 细胞体外生长有抑制作用，其作用机制与调控肿瘤相关基因的表达有关。
Role of sorafenib on inhibition of growth of human hepatocellular carcinoma cells in vitro
Objective: To investigate the influence of sorafenib on growth and expressions of tumor-related genes in human hepatocellular carcinoma (HCC) cells in vitro. Methods: Human HCC cells (Hep3B2.1-7) were exposed to different concentrations (0, 5, 10, and 20 μmol/L) of sorafenib for 24 h, and then, the cell proliferation was analyzed by CCK-8 assay, and the mRNA and protein expressions of p53, PTEN and TGF-β1 in the HCC cells were determined by real-time PCR and Western blot, respectively. Results: Compared with the group of cells with 0 μmol/L sorafenib treatment (control group), in the other groups of cells with sorafenib treatment, the cell proliferation rates were all significantly decreased (all P<0.05); the mRNA and protein expressions of p53 and PTEN were significantly increased, while the mRNA and protein expressions of TGF-β1 were significantly decreased (all P<0.05). All these effects of sorafenib showed a certain concentration-dependent manner. Conclusion: Sorafenib can inhibit the growth of human HCC cells in vitro, and the mechanism may be attributed to its regulating the expressions of tumor-related genes.